Zeiss, Boehringer Ingelheim to focus on early detection of retinal diseases
Click Here to Manage Email Alerts
Key takeaways:
- Zeiss Medical Technology and Boehringer Ingelheim will collaborate on the early detection of eye diseases.
- The companies will leverage cloud-connected devices and AI-assisted analysis of data sets.
Zeiss Medical Technology has partnered with Boehringer Ingelheim to create predictive analytics to aid with early detection of eye diseases.
The companies will use data analytics and algorithms to detect and treat retinal diseases as early as possible.
“With our announcement today with Boehringer Ingelheim, we’re building on our strategy to innovate through partnerships in order to make breakthrough discoveries to combat vision loss and improve people’s lives,” Euan S. Thomson, PhD, head of the ophthalmology strategic business unit and head of the digital business unit for Zeiss Medical Technology, said in a press release. “Enabled by our Zeiss Medical Ecosystem and the platform’s ability to aggregate massive data sets for analysis, we’re strongly positioned to establish new partnerships in pursuit of research yet to be investigated, to accelerate access to future technologies and markets, and to help clinicians provide earlier detection and more personalized and precise care for their patients.”
A main focus of the collaboration will involve the identification of markers of early disease stages through cloud-connected devices and AI-assisted analysis of image data sets. This will allow clinical studies to develop personalized, precise treatments “as well as earlier detection and prediction capabilities to preserve vision through new treatment pathways,” the release said.
Read more about
Click Here to Manage Email Alerts